RPS® Expands Eye Care Organization in Response to InflammaDry® Regulatory Clearance and Growing Demand

Rapid Pathogen Screening, Inc. (RPS®) today announced the expansion of its eye care organization in order to meet growing demand for InflammaDry® – a rapid, disposable, in-office test to aid in the diagnosis of dry eye disease.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
InflammaDry Test Packaging

InflammaDry Test Packaging

Expanding RPS’s commercial organization, including a co-promotional partnership with Allergan, a global leader in eye care, will help to facilitate improved care for the millions of patients who suffer from dry eye disease.

Sarasota, FL (PRWEB) April 15, 2014

Rapid Pathogen Screening, Inc. (RPS®) today announced the expansion of its eye care organization in order to meet growing demand for InflammaDry® – a rapid, disposable, in-office test to aid in the diagnosis of dry eye disease. InflammaDry is the first and only in-office test to detect MMP-9, a clinically relevant inflammatory marker that is consistently elevated in the tears of patients with dry eye disease. RPS is a developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests for infectious diseases and inflammatory conditions.

The InflammaDry test is CE-marked, 510(k) cleared, CLIA-waived, and commercially available in Europe, the United States, Canada, and many other countries throughout the world.

Recent regulatory clearance of the InflammaDry test has been met with enthusiasm from eye care professionals worldwide. In response to this enthusiasm – and under the leadership of Thomas Orsini, president of RPS’s global eye care channel – the company has established a focused eye care sales and marketing team with extensive industry experience to lead the global commercial efforts. Additionally, RPS has entered into a U.S. co-promotional partnership with Allergan, Inc., a global leader in eye care, to increase awareness of dry eye disease related to elevated MMP-9 in tears.

“RPS is emboldened by the positive response following the U.S. clearance of InflammaDry,” said Robert Sambursky, MD, chief executive officer, president, and chairman of RPS. “Expanding RPS’s commercial organization, including a co-promotional partnership with Allergan, a global leader in eye care, will help to facilitate improved care for the millions of patients who suffer from dry eye disease.”

Dry eye is a multifactorial disease that often leads to inflammation and results in discomfort, visual disturbance, and tear film instability, with potential damage to the ocular surface. It is estimated that 25 million people suffer from dry eye in the United States. Factors contributing to dry eye disease include age, environment, medical conditions, and hormonal changes, among others. Left undiagnosed and untreated, episodic dry eye can develop into chronic dry eye. Chronic dry eye can be a progressive disease that, if also left undiagnosed and untreated, can lead to increased risk of infection or further vision problems.

“Understanding more about the complex pathophysiology of chronic dry eye, especially its inflammatory component, has led to more targeted management options for patients with chronic dry eye,” said Mile Brujic, OD. “I am optimistic about the important role that the InflammaDry test will play in helping to improve the diagnosis of dry eye.”

InflammaDry is an affordable, single-use test that requires no additional equipment to administer or interpret results. Using only a small sample of human tears, the simple, four-step InflammaDry process takes less than two minutes to complete and can be performed by a technician during a patient’s initial workup. Results are available for the clinician in just ten minutes, allowing a treatment plan to be established with the patient during their initial office visit.

For more information, visit http://www.InflammaDry.com. To order the InflammaDry test, email info(at)InflammaDry(dot)com or call 941.556.1850.

About RPS
Founded in 2004, Rapid Pathogen Screening, Inc. (RPS) is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to support the rapid diagnosis of patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being developed to help detect the body’s immune response to viral and bacterial infections as well as chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment. Currently available RPS tests include AdenoPlus to aid in the diagnosis of Adenoviral conjunctivitis (pink eye) and InflammaDry to aid in the diagnosis of dry eye disease. For more information on RPS or its products, visit RPSdetectors.com.

Media contact: Laura Lovejoy • laura(at)saranova(dot)net • 941.928.9025


Contact